Salud financiera de hoja de balance de MacroGenics
Salud financiera controles de criterios 6/6
MacroGenics tiene un patrimonio de los accionistas total de $152.6M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $298.4M y $145.8M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$184.24m |
| Patrimonio | US$106.15m |
| Total pasivo | US$142.13m |
| Activos totales | US$248.29m |
Actualizaciones recientes sobre salud financiera
Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25
Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12We're Not Very Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Nov 21Recent updates
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
May 13MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
May 13MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Mar 11Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Oct 25MacroGenics: No Near-Term Catalysts
Oct 11Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics
Sep 02MacroGenics Q2 2022 Earnings Preview
Aug 05Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25MacroGenics halts mid-stage head and neck cancer study after fatalities
Jul 11The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
May 09We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials
Feb 25Estimating The Intrinsic Value Of MacroGenics, Inc. (NASDAQ:MGNX)
Feb 18We're Not Very Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Nov 21MacroGenics: Revisiting Our Pipeline And Investment Analysis
Aug 10MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are More Bearish Than They Used To Be
Aug 03MacroGenics collaborates with Zai Lab to develop bispecific antibodies in oncology
Jun 16Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($251.3M) de MGNX superan a sus pasivos a corto plazo ($56.1M).
Pasivo a largo plazo: Los activos a corto plazo de MGNX ($251.3M) superan a sus pasivos a largo plazo ($89.7M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: MGNX está libre de deudas.
Reducción de la deuda: MGNX no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: MGNX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: MGNX dispone de suficiente cash runway para 1.6 años si el flujo de caja libre sigue creciendo a tasas históricas de 0.5% cada año.